• Amitriptyline HCl: Technical Guidance for Neuropharmacology

  2026-06-13

  Amitriptyline HCl facilitates precise modulation of neurotransmitter receptors in neuropharmacology and CNS-focused research workflows. It is best suited for studies targeting serotonin and norepinephrine receptor pathways. Use is not recommended outside validated neuropsychiatric models or where long-term solution stability is required.

• Streptozotocin (STZ): Beyond β-Cell Cytotoxicity in Diabetes

  2026-06-12

  Discover how Streptozotocin enables advanced diabetes research through selective β-cell cytotoxicity and unique mechanistic insights. This article explores novel applications, protocol optimization, and the latest findings on STZ’s role in modeling diabetic complications.

• WAY-100635: Transforming 5-HT1A Antagonism for Translational

  2026-06-12

  This thought-leadership article explores the mechanistic power and strategic application of WAY-100635 (N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide) as a benchmark serotonin 5-HT1A receptor antagonist. Bridging rigorous neuroscience with translational pain research, it delivers actionable guidance for protocol optimization, interprets cutting-edge findings on serotonergic modulation in pain and emotion, and positions APExBIO’s WAY-100635 as a catalyst for high-impact workflows. Distinct from standard product or workflow guides, this analysis articulates next-generation research opportunities at the intersection of receptor pharmacology, behavioral neuroscience, and multidimensional pain management.

• Palonosetron Hydrochloride: Beyond CINV—Molecular Insights a

  2026-06-11

  Discover how Palonosetron hydrochloride, a highly selective 5-HT3 receptor antagonist, advances both antiemetic precision and renal transporter studies. This article offers fresh mechanistic perspectives and practical guidance for cancer research beyond conventional reviews.

• Perospirone (SM-9018 Free Base): Protocols for Neurovascular

  2026-06-11

  Perospirone (SM-9018 free base) empowers researchers with high-affinity receptor modulation and selective Kv1.5 channel inhibition, uniquely bridging neuropsychiatric and cardiovascular experimental models. This guide details optimized protocols, real-world troubleshooting, and workflow strategies to maximize data reliability and translational relevance.

• Lnc21q22.11 Suppresses Gastric Cancer via MEK/ERK Pathway In

  2026-06-10

  A 2025 Epigenetics study identifies the novel long non-coding RNA Lnc21q22.11 as a suppressor of gastric cancer growth, acting through inhibition of the MEK/ERK signaling pathway. These mechanistic insights highlight new directions for targeted therapy and underscore the technical importance of sensitive detection methods in RNA biology.

• Flavopiridol (L868275): Deep Mechanistic Insights for CDK-Dr

  2026-06-10

  Explore how Flavopiridol, a leading pan-CDK inhibitor, advances cancer research through nuanced mechanisms and evidence-based protocol refinements. This article uniquely dissects cell cycle arrest and apoptosis induction in tumor models, offering new perspectives beyond standard workflows.

• Nicotine Signaling Drives CKD Progression: Mechanisms and Im

  2026-06-09

  Jain and Jaimes dissect how nicotine, via non-neuronal nAChRs, accelerates chronic kidney disease (CKD) progression in smokers by promoting oxidative stress, fibrosis, and hemodynamic shifts. Their review clarifies the molecular and physiological mechanisms underlying nicotine’s contribution to CKD and highlights new avenues for targeted intervention.

• Sumatriptan Succinate: Mechanistic Insights and Metabolic Nu

  2026-06-09

  Explore Sumatriptan Succinate as a 5-HT1 receptor agonist with a focus on its nuanced metabolism, practical assay implications, and translational relevance in migraine research. This article uniquely bridges mechanistic depth and protocol optimization for advanced serotonergic signaling studies.

• Silymarin Research with Silybin A: Protocols and Troubleshoo

  2026-06-08

  Silybin A, the active component of Silymarin, empowers liver disease and metabolic research with high-purity, reproducible results. This guide distills advanced workflows, optimization tactics, and the latest mechanistic insights to help you leverage APExBIO’s Silybin A for cell-based and biochemical assays targeting oxidative stress, hepatoprotection, and cancer signaling.

• Cisapride (R 51619): Benchmarking Cardiotoxicity in iPSC Mod

  2026-06-08

  Explore how Cisapride enables robust benchmarking of cardiotoxicity in iPSC-derived cardiomyocytes, advancing cardiac electrophysiology research. This article uniquely bridges validated assay controls, deep learning, and translational insights for precise drug safety evaluation.

• Parathyroid Hormone (1-34) (Human): Molecular Insights & CKD

  2026-06-07

  Explore how Parathyroid hormone (1-34) (human) advances bone metabolism and valvular calcification research by uncovering molecular mechanisms in chronic kidney disease. This article provides advanced guidance for translational scientists using PTH (1-34) peptide fragment.

• Fluo-4 AM: Fluorescent Calcium Indicator for Advanced Cell A

  2026-06-06

  Fluo-4 AM delivers rapid, high-sensitivity intracellular calcium measurement—ideal for both foundational signaling research and cutting-edge bioelectronic device assessment. Explore optimized protocols, troubleshooting strategies, and the translational impact of this fluorescent calcium indicator in next-generation retinal prosthesis workflows.

• Mianserin HCl: 5-HT2 Receptor Antagonist for Advanced Benchw

  2026-06-05

  Mianserin HCl stands apart as a robust 5-HT2 receptor antagonist and antidepressant research compound, offering unique solubility and inclusion complex options for assay versatility. This article details applied workflows, troubleshooting, and protocol optimization, with actionable insights from recent cyclodextrin interaction studies.

• Acifran: Structural Insights and Benchmarks for Lipid Metabo

  2026-06-05

  Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) is a rigorously characterized, selective HM74A/GPR109A and GPR109B agonist for lipid metabolism research. Recent cryo-EM studies elucidate its binding and mechanism, cementing its role as a gold-standard metabolic disorder research compound.

15740 records 1/1050 page Next 12345 下5页 Last page